It is estimated that the potential market for treatment of atherosclerotic plaque that may rupture and cause heart attack estimated as being in excess of 5billion. 

The Company has successfully enrolled patients in its first clinical study in January 2023, and aims to begin commercialization once it has gained regulatory approval for the product in territories worldwide.